{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-059374","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.836422+00:00","generated_at":"2026-06-08T20:57:54.131126+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Revolution Medicines Q3 net loss $108.4M; updates on RMC-6236, RMC-6291; EQRx close imminent","bullets":["Q3 2023 net loss $108.4M vs $73.3M; revenue $0 vs $3.4M; R&D spend $107.7M (+55%).","Cash $813.2M; updated FY2023 net loss guidance $385-$415M; cash runway into 2025.","Promising clinical data for RMC-6236 (RAS MULTI) and RMC-6291 (RAS G12C); Phase 3 plans for NSCLC and PDAC in 2024.","EQRx acquisition expected to close Nov 2023; all-stock deal, ~55M shares issued, adds ~$1.1B net cash (~$20/share issued)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-059374","json":"https://secwatch.observer/filing/0000950170-23-059374.json","markdown":"https://secwatch.observer/filing/0000950170-23-059374.md","text":"https://secwatch.observer/filing/0000950170-23-059374.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023059374/0000950170-23-059374-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023059374/rvmd-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T20:57:54.131126+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0c1614c67ffbc3b005ee29f6ebbca15ce8ad037e","claim":"Revolution Medicines, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 6, 2023, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023059374/0000950170-23-059374-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}